Mechanism(s) of Airflow Limitation During Exacerbation of Asthma
Status:
Recruiting
Trial end date:
2024-06-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to evaluate the site and mechanisms responsible for expiratory
airflow limitation in chronic, treated, non-smoking, stable asthmatics with moderate to
severe persistent expiratory airflow obstruction. Treatment will include inhaled
corticosteroids and long acting beta2agonists. The investigators are interested in
determining whether the large and/or small airways are the predominant site of airflow
limitation. The investigators are also interested in determining whether intrinsic small
airways obstruction and/or loss of lung elastic recoil is responsible for expiratory airflow
limitation. The investigators are also interested to evaluate the role of varying doses of
inhaled corticosteroids to suppress large and small airway inflammation using exhaled nitric
oxide as surrogate markers of inflammation. For comparison purposes, spirometry and
measurements of exhaled nitric oxide will also be obtained if possible during a naturally
occurring exacerbation of asthma.
Phase:
Phase 4
Details
Lead Sponsor:
Gelb, Arthur F., M.D.
Treatments:
Budesonide Budesonide, Formoterol Fumarate Drug Combination Fluticasone Fluticasone Propionate, Salmeterol Xinafoate Drug Combination Fluticasone-Salmeterol Drug Combination Formoterol Fumarate Salmeterol Xinafoate Xhance